Physician profile
Amy E Sullinger
NPI 1619509494
$6,280.60
in general payments reported to CMS, 2019-2025
27 companies · $2,263 in 2025
The $2,263 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $170 · 2022: $1,348 · 2023: $901 · 2024: $1,599 · 2025: $2,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,642 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,642.46 |
| Education | $120.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $952.34 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $885.58 | 2022-2025 | Tremfya |
| Genzyme Corporation | $505.73 | 2022-2025 | |
| Allergan, INC. | $484.77 | 2022 | |
| Ucb, INC. | $407.33 | 2024-2025 | Bimzelx |
| Abbvie INC. | $383.14 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $380.72 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $377.90 | 2022-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $243.20 | 2022-2023 | Sotyktu |
| Pfizer INC. | $232.44 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $221.83 | 2021-2025 | |
| Amgen INC. | $216.56 | 2024-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $155.98 | 2023-2024 | Vtama |
| Incyte Corporation | $146.87 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $134.63 | 2024-2025 | Nemluvio |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.05 | 2024-2025 | Spevigo |
| Lilly USA, LLC | $77.61 | 2022-2025 | Taltz, Ebglyss |
| Verrica Pharmaceuticals INC. | $69.72 | 2024-2025 | Ycanth |
| Sanofi-Aventis U.S. LLC | $55.99 | 2025 | |
| Organon LLC | $46.35 | 2025 | Vtama |
| Botanix Sb INC | $43.53 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $27.60 | 2024 | |
| Convatec INC. | $26.13 | 2025 | |
| Cipher Pharmaceuticals US LLC | $25.58 | 2025 | Natroba, Spinosad |
| Sun Pharmaceutical Industries INC. | $24.20 | 2024 | |
| Journey Medical Corporation | $22.69 | 2022 | |
| Smith+Nephew, INC. | $21.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Sullinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.